Stoke Therapeutics, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Stoke Therapeutics reported Q3 2026 net loss of $73.6M ($1.08/share) versus $38.3M loss ($0.65/share) in Q3 2025, driven by increased R&D expenses of $59.8M (up from $37.7M) and SG&A of $28.7M (up from $16.0M) to support zorevunersen advancement. The Phase 3 EMPEROR study for Dravet syndrome enrollment completed with 162 patients in primary analysis; ~110 have reached Week 28 primary endpoint and ~20 through Week 52, with data readout anticipated Q3 2027 and NDA submission H2 2027. Cash position of $358.8M is expected to fund operations into early 2028. STK-002 for ADOA advanced with third cohort dosing underway; initial safety/efficacy data expected H1 2027.
Why this rating
Trial progress on-track but no new efficacy data; high cash burn ($185.3M YTD loss) against $359M runway represents moderate concern relative to ~$592M market cap.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.